Methyl-CpG-Binding Domain Protein 2 Controls hTERT Expression in Cancer Cells

Strategic Insights -

Cancer gene therapy researchers have identified a key player in the regulation of telomerase activity in cancer cells. According to a study published in Carcinogenesis, methyl-CpG-binding domain protein 2 (MBD2) is specifically involved in the transcriptional repression of human telomerase reverse transcriptase (hTERT) in HeLa cells and other cancer cell lines.

The study, conducted by A. Chatagnon and colleagues at INSERM, Lyon, France, found that MBD2 associates with the hypermethylated hTERT promoter and represses its transcription. Depletion of MBD2 in HeLa cells led to an upregulation of hTERT transcription, which could be downregulated by expressing mouse Mbd2 protein. This specific transcriptional repression was observed in breast, liver, and neuroblastoma cancer cell lines, suggesting that MBD2 is a general repressor of hTERT in telomerase-positive cells.

Key Takeaways:

  • Methyl-CpG-binding domain protein 2 (MBD2) is specifically involved in the transcriptional repression of human telomerase reverse transcriptase (hTERT) in HeLa cells and other cancer cell lines.
  • MBD2 associates with the hypermethylated hTERT promoter and represses its transcription.
  • Depletion of MBD2 in HeLa cells leads to an upregulation of hTERT transcription.
  • The specific transcriptional repression of hTERT by MBD2 was observed in breast, liver, and neuroblastoma cancer cell lines.
  • Mouse Mbd2 protein can downregulate hTERT transcription in MBD2-depleted HeLa cells.
  • MBD2 may be a general repressor of hTERT in telomerase-positive cells.
  • Consideration of MBD2 as a potential target for cancer therapy is supported by the study's findings.

Statistics:

  • 28-34: The page numbers of the study published in Carcinogenesis (Chatagnon et al., 2009).
  • 30: The volume number of the study published in Carcinogenesis (Chatagnon et al., 2009).
  • 1: The issue number of the study published in Carcinogenesis (Chatagnon et al., 2009).

Sources:

  • Chatagnon, A., et al. (2009). Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis, 30(1), 28-34.
  • INSERM U590, Lyon, France.
  • Oxford University Press, Great Clarendon St., Oxford OX2 6DP, England.